ABSTRACT
Background:Estrogen [ER] and progesterone [PR] are important factors in prognosis and treatment of breast cancer patients. Many studies suggest that disease free survival [DFS] differs when one of these receptors is positive and the other is negative. We aim to study the impact of positivity of estrogen receptors comparing with progesterone receptors on DFS in early breast cancer
Patients and Methods: Asingle institute retrospective study was performed of 224 patients with early breast cancer, stage I, II, IIIa, between 2008 and 2010. The patients underwent mastectomy or lumpectomy and received adjuvant hormone therapy. This study has two arms: Group A [patients with ER positive, PR negative n = 127]. Group B [patients with PR positive, ER negative n = 97]. The endpoint was 3-year disease free survival in both arms
Results: The 3-year disease free survival in the group A was 75.8 percent, while it was 77.2 percent in group B [p = 0.31]
Conclusion: There is no difference between the impact of estrogen receptors positivity and progesterone receptors positivity on disease free survival in the treatment of early breast cancer